CinnaGen 
Welcome,         Profile    Billing    Logout  
 10 Products   2 Diseases  10 Products   8 Trials   247 News 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ituxredi (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R-Pharm
RI-01-007, NCT04268771 / 2019-002810-37: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Completed
3
140
US
Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
Dr. Reddy's Laboratories Limited, PPD
Rheumatoid Arthritis
01/22
04/22
FLINTER, NCT03976102 / 2018-004223-36: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

Completed
3
317
US
DRL_RI (Proposed rituximab biosimilar), MabThera®
Dr. Reddy's Laboratories Limited, Parexel
Follicular Lymphoma
09/22
02/23
NCT05078177: Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Recruiting
1
40
RoW
Rituximab, Mabthera, Reditux, Acellbia
St. Petersburg State Pavlov Medical University
Multiple Sclerosis
12/22
12/24
Reditux1: A therapeutic and side effects’ comparison between Reditux and brand type (MabThera) in Diffuse Large B Cell Lymphoma (DLBCL)

Completed
N/A
30
RestOfWorld
Reditux (rituximab biosimilar)
Lymphoma
 
 
CinnoVex (IFN-β-1a biosimilar) / CinnaGen
IRCT20150914024017N1: The efficacy of Interferon beta 1 a (ReciGen) in treatment of patients with Covid-19 in Sina Hospital Emergency Department

Recruiting
3
40
Tehran
CinnoVex (IFN-β-1a biosimilar) - CinnaGen
CinnoVex, ReciGen
Covid-19
 
 
IRCT20100228003449N2: Evaluating efficacy and safety of interferone β-1a in the treatment COVID-19 infection

Active, not recruiting
3
30
Tehran
CinnoVex (IFN-β-1a biosimilar) - CinnaGen
CinnaGen
COVID-19
 
 
cetuximab biosimilar / CinnaGen
NCT03391934: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Recruiting
3
234
RoW
Cetuximab + FOLFIRI, FOLFIRI = irinotecan + calcium folinate + 5-fluorouracil
Cinnagen
Metastatic Colorectal Cancer
11/25
02/26
COVAX-19 (GC004) / Flinders University, Vaxine, GeneCure Biotechnologies, Medytox, CinnaGen
NCT05279456: A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

Active, not recruiting
3
39
RoW
Advax-CpG55.2 adjuvanted recombinant spike protein, Spikogen vaccine
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute
COVID-19
12/23
10/24
NCT05542862: Booster Study of SpikoGen COVID-19 Vaccine

Active, not recruiting
3
150
RoW
SpikoGen vaccine, Covax-19
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd, Cinnagen
COVID-19
12/23
10/24
NCT05148871: Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Active, not recruiting
2/3
200
RoW
Spikogen/Covax-19
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute, Cinnagen
COVID-19
02/23
10/24
NCT05285384: Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

Completed
N/A
43
RoW
SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SpikoGen, COVAX-19
Cinnagen, Shahid Beheshti University of Medical Sciences, Vaxine Pty Ltd
COVID-19
03/22
03/22
P013 (pertuzumab biosimilar) / CinnaGen
No trials found
Xacrel (ocrelizumab biosimilar) / CinnaGen
No trials found
Tyalia (aflibercept biosimilar) / CinnaGen
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ituxredi (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R-Pharm
RI-01-007, NCT04268771 / 2019-002810-37: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Completed
3
140
US
Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
Dr. Reddy's Laboratories Limited, PPD
Rheumatoid Arthritis
01/22
04/22
FLINTER, NCT03976102 / 2018-004223-36: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

Completed
3
317
US
DRL_RI (Proposed rituximab biosimilar), MabThera®
Dr. Reddy's Laboratories Limited, Parexel
Follicular Lymphoma
09/22
02/23
NCT05078177: Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Recruiting
1
40
RoW
Rituximab, Mabthera, Reditux, Acellbia
St. Petersburg State Pavlov Medical University
Multiple Sclerosis
12/22
12/24
Reditux1: A therapeutic and side effects’ comparison between Reditux and brand type (MabThera) in Diffuse Large B Cell Lymphoma (DLBCL)

Completed
N/A
30
RestOfWorld
Reditux (rituximab biosimilar)
Lymphoma
 
 
CinnoVex (IFN-β-1a biosimilar) / CinnaGen
IRCT20150914024017N1: The efficacy of Interferon beta 1 a (ReciGen) in treatment of patients with Covid-19 in Sina Hospital Emergency Department

Recruiting
3
40
Tehran
CinnoVex (IFN-β-1a biosimilar) - CinnaGen
CinnoVex, ReciGen
Covid-19
 
 
IRCT20100228003449N2: Evaluating efficacy and safety of interferone β-1a in the treatment COVID-19 infection

Active, not recruiting
3
30
Tehran
CinnoVex (IFN-β-1a biosimilar) - CinnaGen
CinnaGen
COVID-19
 
 
cetuximab biosimilar / CinnaGen
NCT03391934: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Recruiting
3
234
RoW
Cetuximab + FOLFIRI, FOLFIRI = irinotecan + calcium folinate + 5-fluorouracil
Cinnagen
Metastatic Colorectal Cancer
11/25
02/26
COVAX-19 (GC004) / Flinders University, Vaxine, GeneCure Biotechnologies, Medytox, CinnaGen
NCT05279456: A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

Active, not recruiting
3
39
RoW
Advax-CpG55.2 adjuvanted recombinant spike protein, Spikogen vaccine
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute
COVID-19
12/23
10/24
NCT05542862: Booster Study of SpikoGen COVID-19 Vaccine

Active, not recruiting
3
150
RoW
SpikoGen vaccine, Covax-19
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd, Cinnagen
COVID-19
12/23
10/24
NCT05148871: Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Active, not recruiting
2/3
200
RoW
Spikogen/Covax-19
Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute, Cinnagen
COVID-19
02/23
10/24
NCT05285384: Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

Completed
N/A
43
RoW
SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SpikoGen, COVAX-19
Cinnagen, Shahid Beheshti University of Medical Sciences, Vaxine Pty Ltd
COVID-19
03/22
03/22
P013 (pertuzumab biosimilar) / CinnaGen
No trials found
Xacrel (ocrelizumab biosimilar) / CinnaGen
No trials found
Tyalia (aflibercept biosimilar) / CinnaGen
No trials found

Download Options